Nucleus is redefining DTC genetic testing. By combining polygenic scores with traditional rare variant DNA analysis, the company provides comprehensive assessments of genetic disposition across a myriad of diseases and traits. Nucleus' mission is to empower people to take agency over their health so no one dies from preventable disease -- that's why the company is building a platform based on cutting-edge science, where everyone has their genome in their pocket, complete clarity on their risks, and are empowered by personalized health measures. Nucleus is also bridging the gap between people, doctors, and scientists to help discoveries, therapies, and cures find their way to people faster.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/14/22 | $14,000,000 | Venture |
Adrian Aoun Alexandra Botez Anthony Pompliano Austen Allred Brent Saunders Founders Fund Hugo Barra Packy McCormick Patrick Hsu Seven Seven Six  Shrug Capital | undisclosed |
